Omalizumab in Food Allergy - Retrospective data analysis (OFAR)

Study identification

• EU PAS number:
  EUPAS1000000585
• Study ID:
  1000000585
• Official title and acronym:
  Omalizumab in Food Allergy - Retrospective data analysis (OFAR)
• DARWIN EU® study:
  No
• Study countries:
  Germany

  Spain

  Switzerland
• Study description:
  Retrospective, multi-center observational study conducted across four allergy departments in Europe (Berlin, Leipzig, Barcelona, and Basel). ; The study included patients with IgE-mediated food allergy who were treated with omalizumab, either as monotherapy or in combination with oral immunotherapy (OIT) between 2002–2022. The study included adult patients diagnosed with IgE-mediated food allergy who received omalizumab treatment between 2002 and 2022.
• Study status:
  Finalised

Research institutions and networks

Institutions

Institute of Clinical Pharmacology and Toxicology (PVZ FAKOS), Charite Universitaetsmedizin Berlin

Germany

Study timelines

Date when funding contract was signed

Actual: 04/10/2021

Study start date

Planned: 24/07/2022

Actual: 01/06/2023

Data analysis start date

Actual: 01/09/2023

Date of final study report

Actual: 22/04/2025

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Novartis Pharma AG

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable

Other study registration identification numbers and links

CIGE025A2010